HeraMED trading halt request details

HeraMED Limited (ASX: $HMD) has requested a trading halt for its ordinary shares on the Australian Securities Exchange (ASX) effective immediately on 6 June 2024. The halt is pending an announcement by HeraMED regarding the termination of a US Partnership. The company has requested that the trading halt remain in place until the earlier of the opening of trade on Tuesday, 11 June 2024, or the release of an announcement by the Company. The purpose of the trading halt is to assist in managing its disclosure obligations and to maintain an orderly market in the trading of the Company's shares.

Executive Commentary

HeraMED has requested the trading halt to ensure that the termination of the US Partnership is communicated to the market in an orderly manner. This decision aligns with our commitment to transparency and compliance with disclosure obligations. We believe that this approach will provide all stakeholders with equal access to the information and maintain the integrity of the market.

Summary of HeraMED's Trading Halt Request

HeraMED Limited (ASX: $HMD) has requested a trading halt to facilitate the announcement of the termination of a US Partnership. The company aims to manage its disclosure obligations and maintain an orderly market in the trading of its shares. The request indicates HeraMED's commitment to transparency and compliance with disclosure obligations. The trading halt is expected to be in place until the earlier of the opening of trade on Tuesday, 11 June 2024, or the release of an announcement by the Company. HeraMED confirms that it is not aware of any reason why the trading halt should not be granted and is not aware of any other information necessary to inform the market about the trading halt.